StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Manas Jaiswal

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byManas JaiswalHorizon: 1–3 months22 Oct 2026via CNBC Awaaz.

Entry₹1,140Stated
Target₹1,160
Total upside +1.75%
Stop loss₹1,124-1.40% risk
CMP₹1,1352h ago
Active-0.44%+2.20%upside left 3 mo left
Follow Manas Jaiswal for new calls(36% target hit, 36 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 44 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 7:07 pm IST
13 supporting3 neutral6 opposing
Supports the BUY call (13)

RSI at 30 — oversold territory

Technicals · rsi·22 Oct · today

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · yesterday

(opens in new tab)

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · yesterday

(opens in new tab)

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · yesterday

(opens in new tab)

Zydus Sunshine Lifesciences has signed an agreement with the Sri Lankan Board of Investment to set up a pharmaceutical manufacturing facility.

BSE · Company Update·15 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (3)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 12 days

(opens in new tab)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · 3w ago

(opens in new tab)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (6)

MACD below its signal line — bearish momentum

Technicals · macd·22 Oct · today

Past month's volume 1.3× the prior month's average

Technicals · volume·21 Oct · yesterday

Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations

NewsCnbc-Tv18·13 Oct · 1w ago

(opens in new tab)

The USFDA concluded an inspection of Zydus Lifesciences' Moraiya manufacturing plant with 5 observations, which the company intends to address.

NSE · Press Release·13 Oct · 1w ago

(opens in new tab)

The USFDA concluded an inspection of the company's Moraiya manufacturing plant with 5 observations.

BSE · Company Update·13 Oct · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Manas Jaiswal

Every call and its outcome